 | • レポートコード：B-GIR08C0607 • 出版社/出版日：GlobalInfoResearch / 2019年8月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール • 産業分類：Pharma & Healthcare |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、アヴェルマブの世界市場について調べ、まとめました。種類別セグメントは、注入等、用途別セグメントは、メルケル細胞癌、非小細胞肺癌（NSCLC）、その他等に区分しました。アヴェルマブの世界市場概観、企業動向、企業別アヴェルマブシェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、アジア等）、主要国分析（日本、中国、アメリカ等）データなどの情報が含まれています。 ・アヴェルマブの市場概観 ・アヴェルマブの企業概要（事業概要、製品種類、販売量、価格、売上、市場シェア等） ・アヴェルマブの企業別販売動向、市場シェア、市場集中度、競争動向 ・アヴェルマブの世界市場規模 ・アヴェルマブの北米市場分析（アメリカ、カナダ、メキシコ等） ・アヴェルマブのアメリカ市場規模推移 ・アヴェルマブのカナダ市場規模推移 ・アヴェルマブのメキシコ市場規模推移 ・アヴェルマブのヨーロッパ市場分析（ドイツ、イギリス、ロシア、フランス、イタリア等） ・アヴェルマブのドイツ市場規模推移 ・アヴェルマブのイギリス市場規模推移 ・アヴェルマブのロシア市場規模推移 ・アヴェルマブのアジア太平洋市場分析（日本、中国、韓国、インド、東南アジア等） ・アヴェルマブの日本市場規模推移 ・アヴェルマブの中国市場規模推移 ・アヴェルマブの韓国市場規模推移 ・アヴェルマブのインド市場規模推移 ・アヴェルマブの東南アジア市場規模推移 ・アヴェルマブの南米市場分析（ブラジル、アルゼンチン等） ・アヴェルマブの中東・アフリカ市場分析（サウジアラビア、UAE、南アフリカ等） ・アヴェルマブの種類別分析/販売量、売上、市場シェア（注入） ・アヴェルマブの用途別分析/市場規模（メルケル細胞癌、非小細胞肺癌（NSCLC）、その他） ・アヴェルマブの市場予測2019年-2024年（地域別予測、種類別予測、用途別予測） ・アヴェルマブの販売チャネル・代理店・貿易業者・ディーラー分析 |
Scope of the Report:
The worldwide market for Avelumab is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Avelumab in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Merck
Pfizer
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Injection
Market Segment by Applications, can be divided into
Merkel-cell Carcinoma
Non-small Cell Lung Carcinoma (NSCLC)
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Avelumab product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Avelumab, with price, sales, revenue and global market share of Avelumab in 2017 and 2018.
Chapter 3, the Avelumab competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Avelumab breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Avelumab market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Avelumab sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Avelumab Introduction
1.2 Market Analysis by Type
1.2.1 Injection
1.3 Market Analysis by Applications
1.3.1 Merkel-cell Carcinoma
1.3.2 Non-small Cell Lung Carcinoma (NSCLC)
1.3.3 Other
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2014-2024)
1.4.1.2 Canada Market States and Outlook (2014-2024)
1.4.1.3 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2014-2024)
1.4.2.2 France Market States and Outlook (2014-2024)
1.4.2.3 UK Market States and Outlook (2014-2024)
1.4.2.4 Russia Market States and Outlook (2014-2024)
1.4.2.5 Italy Market States and Outlook (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2014-2024)
1.4.3.2 Japan Market States and Outlook (2014-2024)
1.4.3.3 Korea Market States and Outlook (2014-2024)
1.4.3.4 India Market States and Outlook (2014-2024)
1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2014-2024)
1.4.4.2 Egypt Market States and Outlook (2014-2024)
1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
1.4.4.4 South Africa Market States and Outlook (2014-2024)
1.4.4.5 Turkey Market States and Outlook (2014-2024)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Merck
2.1.1 Business Overview
2.1.2 Avelumab Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Merck Avelumab Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.2 Pfizer
2.2.1 Business Overview
2.2.2 Avelumab Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Pfizer Avelumab Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Avelumab Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
3.1 Global Avelumab Sales and Market Share by Manufacturer (2017-2018)
3.2 Global Avelumab Revenue and Market Share by Manufacturer (2017-2018)
3.3 Market Concentration Rate
3.3.1 Top 3 Avelumab Manufacturer Market Share in 2018
3.3.2 Top 6 Avelumab Manufacturer Market Share in 2018
3.4 Market Competition Trend
4 Global Avelumab Market Analysis by Regions
4.1 Global Avelumab Sales, Revenue and Market Share by Regions
4.1.1 Global Avelumab Sales and Market Share by Regions (2014-2019)
4.1.2 Global Avelumab Revenue and Market Share by Regions (2014-2019)
4.2 North America Avelumab Sales and Growth Rate (2014-2019)
4.3 Europe Avelumab Sales and Growth Rate (2014-2019)
4.4 Asia-Pacific Avelumab Sales and Growth Rate (2014-2019)
4.5 South America Avelumab Sales and Growth Rate (2014-2019)
4.6 Middle East and Africa Avelumab Sales and Growth Rate (2014-2019)
5 North America Avelumab by Country
5.1 North America Avelumab Sales, Revenue and Market Share by Country
5.1.1 North America Avelumab Sales and Market Share by Country (2014-2019)
5.1.2 North America Avelumab Revenue and Market Share by Country (2014-2019)
5.2 United States Avelumab Sales and Growth Rate (2014-2019)
5.3 Canada Avelumab Sales and Growth Rate (2014-2019)
5.4 Mexico Avelumab Sales and Growth Rate (2014-2019)
6 Europe Avelumab by Country
6.1 Europe Avelumab Sales, Revenue and Market Share by Country
6.1.1 Europe Avelumab Sales and Market Share by Country (2014-2019)
6.1.2 Europe Avelumab Revenue and Market Share by Country (2014-2019)
6.2 Germany Avelumab Sales and Growth Rate (2014-2019)
6.3 UK Avelumab Sales and Growth Rate (2014-2019)
6.4 France Avelumab Sales and Growth Rate (2014-2019)
6.5 Russia Avelumab Sales and Growth Rate (2014-2019)
6.6 Italy Avelumab Sales and Growth Rate (2014-2019)
7 Asia-Pacific Avelumab by Country
7.1 Asia-Pacific Avelumab Sales, Revenue and Market Share by Country
7.1.1 Asia-Pacific Avelumab Sales and Market Share by Country (2014-2019)
7.1.2 Asia-Pacific Avelumab Revenue and Market Share by Country (2014-2019)
7.2 China Avelumab Sales and Growth Rate (2014-2019)
7.3 Japan Avelumab Sales and Growth Rate (2014-2019)
7.4 Korea Avelumab Sales and Growth Rate (2014-2019)
7.5 India Avelumab Sales and Growth Rate (2014-2019)
7.6 Southeast Asia Avelumab Sales and Growth Rate (2014-2019)
8 South America Avelumab by Country
8.1 South America Avelumab Sales, Revenue and Market Share by Country
8.1.1 South America Avelumab Sales and Market Share by Country (2014-2019)
8.1.2 South America Avelumab Revenue and Market Share by Country (2014-2019)
8.2 Brazil Avelumab Sales and Growth Rate (2014-2019)
8.3 Argentina Avelumab Sales and Growth Rate (2014-2019)
8.4 Colombia Avelumab Sales and Growth Rate (2014-2019)
9 Middle East and Africa Avelumab by Countries
9.1 Middle East and Africa Avelumab Sales, Revenue and Market Share by Country
9.1.1 Middle East and Africa Avelumab Sales and Market Share by Country (2014-2019)
9.1.2 Middle East and Africa Avelumab Revenue and Market Share by Country (2014-2019)
9.2 Saudi Arabia Avelumab Sales and Growth Rate (2014-2019)
9.3 Turkey Avelumab Sales and Growth Rate (2014-2019)
9.4 Egypt Avelumab Sales and Growth Rate (2014-2019)
9.5 Nigeria Avelumab Sales and Growth Rate (2014-2019)
9.6 South Africa Avelumab Sales and Growth Rate (2014-2019)
10 Global Avelumab Market Segment by Type
10.1 Global Avelumab Sales, Revenue and Market Share by Type (2014-2019)
10.1.1 Global Avelumab Sales and Market Share by Type (2014-2019)
10.1.2 Global Avelumab Revenue and Market Share by Type (2014-2019)
10.2 Injection Sales Growth and Price
10.2.1 Global Injection Sales Growth (2014-2019)
10.2.2 Global Injection Price (2014-2019)
11 Global Avelumab Market Segment by Application
11.1 Global Avelumab Sales Market Share by Application (2014-2019)
11.2 Merkel-cell Carcinoma Sales Growth (2014-2019)
11.3 Non-small Cell Lung Carcinoma (NSCLC) Sales Growth (2014-2019)
11.4 Other Sales Growth (2014-2019)
12 Avelumab Market Forecast (2019-2024)
12.1 Global Avelumab Sales, Revenue and Growth Rate (2019-2024)
12.2 Avelumab Market Forecast by Regions (2019-2024)
12.2.1 North America Avelumab Market Forecast (2019-2024)
12.2.2 Europe Avelumab Market Forecast (2019-2024)
12.2.3 Asia-Pacific Avelumab Market Forecast (2019-2024)
12.2.4 South America Avelumab Market Forecast (2019-2024)
12.2.5 Middle East and Africa Avelumab Market Forecast (2019-2024)
12.3 Avelumab Market Forecast by Type (2019-2024)
12.3.1 Global Avelumab Sales Forecast by Type (2019-2024)
12.3.2 Global Avelumab Market Share Forecast by Type (2019-2024)
12.4 Avelumab Market Forecast by Application (2019-2024)
12.4.1 Global Avelumab Sales Forecast by Application (2019-2024)
12.4.2 Global Avelumab Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
Figure Avelumab Picture
Table Product Specifications of Avelumab
Figure Global Sales Market Share of Avelumab by Types in 2018
Table Avelumab Types for Major Manufacturers
Figure Injection Picture
Figure Avelumab Sales Market Share by Applications in 2018
Figure Merkel-cell Carcinoma Picture
Figure Non-small Cell Lung Carcinoma (NSCLC) Picture
Figure Other Picture
Figure United States Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Canada Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Mexico Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Germany Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure France Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure UK Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Russia Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Italy Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure China Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Japan Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Korea Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure India Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Southeast Asia Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Brazil Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Egypt Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Saudi Arabia Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure South Africa Avelumab Revenue (Value) and Growth Rate (2014-2024)
Figure Nigeria Avelumab Revenue (Value) and Growth Rate (2014-2024)
Table Merck Basic Information, Manufacturing Base and Competitors
Table Merck Avelumab Type and Applications
Table Merck Avelumab Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer Avelumab Type and Applications
Table Pfizer Avelumab Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
Table Global Avelumab Sales by Manufacturer (2017-2018)
Figure Global Avelumab Sales Market Share by Manufacturer in 2017
Figure Global Avelumab Sales Market Share by Manufacturer in 2018
Table Global Avelumab Revenue by Manufacturer (2017-2018)
Figure Global Avelumab Revenue Market Share by Manufacturer in 2017
Figure Global Avelumab Revenue Market Share by Manufacturer in 2018
Figure Top 3 Avelumab Manufacturer (Revenue) Market Share in 2018
Figure Top 6 Avelumab Manufacturer (Revenue) Market Share in 2018
Figure Global Avelumab Sales and Growth Rate (2014-2019)
Figure Global Avelumab Revenue and Growth Rate (2014-2019)
Table Global Avelumab Sales by Regions (2014-2019)
Table Global Avelumab Sales Market Share by Regions (2014-2019)
Table Global Avelumab Revenue by Regions (2014-2019)
Figure Global Avelumab Revenue Market Share by Regions (2014-2019)
Figure Global Avelumab Revenue Market Share by Regions in 2018
Figure North America Avelumab Sales and Growth Rate (2014-2019)
Figure Europe Avelumab Sales and Growth Rate (2014-2019)
Figure Asia-Pacific Avelumab Sales and Growth Rate (2014-2019)
Figure South America Avelumab Sales and Growth Rate (2014-2019)
Figure Middle East and Africa Avelumab Sales and Growth Rate (2014-2019)
Figure North America Avelumab Revenue and Growth Rate (2014-2019)
Table North America Avelumab Sales by Countries (2014-2019)
Table North America Avelumab Sales Market Share by Countries (2014-2019)
Figure North America Avelumab Sales Market Share by Countries (2014-2019)
Figure North America Avelumab Sales Market Share by Countries in 2018
Table North America Avelumab Revenue by Countries (2014-2019)
Table North America Avelumab Revenue Market Share by Countries (2014-2019)
Figure North America Avelumab Revenue Market Share by Countries (2014-2019)
Figure North America Avelumab Revenue Market Share by Countries in 2018
Figure United States Avelumab Sales and Growth Rate (2014-2019)
Figure Canada Avelumab Sales and Growth Rate (2014-2019)
Figure Mexico Avelumab Sales and Growth Rate (2014-2019)
Figure Europe Avelumab Revenue and Growth Rate (2014-2019)
Table Europe Avelumab Sales by Countries (2014-2019)
Table Europe Avelumab Sales Market Share by Countries (2014-2019)
Table Europe Avelumab Revenue by Countries (2014-2019)
Figure Europe Avelumab Revenue Market Share by Countries (2014-2019)
Figure Europe Avelumab Revenue Market Share by Countries in 2018
Figure Germany Avelumab Sales and Growth Rate (2014-2019)
Figure UK Avelumab Sales and Growth Rate (2014-2019)
Figure France Avelumab Sales and Growth Rate (2014-2019)
Figure Russia Avelumab Sales and Growth Rate (2014-2019)
Figure Italy Avelumab Sales and Growth Rate (2014-2019)
Figure Asia-Pacific Avelumab Revenue and Growth Rate (2014-2019)
Table Asia-Pacific Avelumab Sales by Countries (2014-2019)
Table Asia-Pacific Avelumab Sales Market Share by Countries (2014-2019)
Figure Asia-Pacific Avelumab Sales Market Share by Countries 2018
Table Asia-Pacific Avelumab Revenue by Countries (2014-2019)
Figure Asia-Pacific Avelumab Revenue Market Share by Countries 2018
Figure China Avelumab Sales and Growth Rate (2014-2019)
Figure Japan Avelumab Sales and Growth Rate (2014-2019)
Figure Korea Avelumab Sales and Growth Rate (2014-2019)
Figure India Avelumab Sales and Growth Rate (2014-2019)
Figure Southeast Asia Avelumab Sales and Growth Rate (2014-2019)
Figure South America Avelumab Revenue and Growth Rate (2014-2019)
Table South America Avelumab Sales by Countries (2014-2019)
Table South America Avelumab Sales Market Share by Countries (2014-2019)
Figure South America Avelumab Sales Market Share by Countries in 2018
Table South America Avelumab Revenue by Countries (2014-2019)
Table South America Avelumab Revenue Market Share by Countries (2014-2019)
Figure South America Avelumab Revenue Market Share by Countries in 2018
Figure Brazil Avelumab Sales and Growth Rate (2014-2019)
Figure Argentina Avelumab Sales and Growth Rate (2014-2019)
Figure Colombia Avelumab Sales and Growth Rate (2014-2019)
Figure Middle East and Africa Avelumab Revenue and Growth Rate (2014-2019)
Table Middle East and Africa Avelumab Sales by Countries (2014-2019)
Table Middle East and Africa Avelumab Sales Market Share by Countries (2014-2019)
Figure Middle East and Africa Avelumab Sales Market Share by Countries in 2018
Table Middle East and Africa Avelumab Revenue by Countries (2014-2019)
Table Middle East and Africa Avelumab Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Avelumab Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Avelumab Revenue Market Share by Countries in 2018
Figure Saudi Arabia Avelumab Sales and Growth Rate (2014-2019)
Figure UAE Avelumab Sales and Growth Rate (2014-2019)
Figure Egypt Avelumab Sales and Growth Rate (2014-2019)
Figure Nigeria Avelumab Sales and Growth Rate (2014-2019)
Figure South Africa Avelumab Sales and Growth Rate (2014-2019)
Table Global Avelumab Sales by Type (2014-2019)
Table Global Avelumab Sales Share by Type (2014-2019)
Table Global Avelumab Revenue by Type (2014-2019)
Table Global Avelumab Revenue Share by Type (2014-2019)
Figure Global Injection Sales Growth (2014-2019)
Figure Global Injection Price (2014-2019)
Table Global Avelumab Sales by Application (2014-2019)
Table Global Avelumab Sales Share by Application (2014-2019)
Figure Global Non-small Cell Lung Carcinoma (NSCLC) Sales Growth (2014-2019)
Figure Global Other Sales Growth (2014-2019)
Figure Global Avelumab Sales, Revenue and Growth Rate (2019-2024)
Table Global Avelumab Sales Forecast by Regions (2019-2024)
Table Global Avelumab Market Share Forecast by Regions (2019-2024)
Figure North America Sales Avelumab Market Forecast (2019-2024)
Figure Europe Sales Avelumab Market Forecast (2019-2024)
Figure Asia-Pacific Sales Avelumab Market Forecast (2019-2024)
Figure South America Sales Avelumab Market Forecast (2019-2024)
Figure Middle East and Africa Sales Avelumab Market Forecast (2019-2024)
Table Global Avelumab Sales Forecast by Type (2019-2024)
Table Global Avelumab Market Share Forecast by Type (2019-2024)
Table Global Avelumab Sales Forecast by Application (2019-2024)
Table Global Avelumab Market Share Forecast by Application (2019-2024)
Table Distributors/Traders/ Dealers List
NSCLC用標的薬物MEK阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drug MEK Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especia…- PD-1阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global PD-1 Inhibitor market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in China, also fast …
- NSCLC用標的薬剤VEGFR2阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drug VEGFR2 Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, espe…
- NSCLC用標的薬BRAF阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drug BRAF Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especi…
- 腎細胞癌治療薬市場：世界及び中国市場分析・予測（～2024年） Renal Cell Carcinoma Drugs Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Renal Cell Carcinoma Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the Renal Cell Carci…